Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial - Wikidata - wikimedia - TriplyDB

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

http://www.wikidata.org/entity/Q33837706

about

Short-course versus prolonged-course antituberculous treatment in tuberculous meningitis Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis Quality of outcome reporting in phase II studies in pulmonary tuberculosis Current prospects for the fluoroquinolones as first-line tuberculosis therapy Antituberculosis therapy for 2012 and beyond A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase Six months therapy for tuberculous meningitis Assessment of treatment response in tuberculosis New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis Gender analysis of moxifloxacin clinical trials Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis Pipeline of drugs for related diseases: tuberculosis Recent advances in tuberculosis: New drugs and treatment regimens.Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.T-SPOT.TB responses during treatment of pulmonary tuberculosis.Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions.Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.Current approaches to tuberculosis in the United States.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

P2860

Q24186210-AE34BFDF-DAF0-4AD3-99D2-491F854DE6BF Q24202081-F4F3C08D-5DCA-48C4-BD28-364E3A085EBD Q26771997-2C136EEF-E292-4EF8-9BB7-6561E030046F Q26775757-9C6233D2-F004-4835-81D0-B06BA3B7D756 Q26777160-43943495-5032-458A-A9E0-7DFA8423163D Q26823843-581C7E57-073E-4A87-896C-5E5063CCDF2B Q26829101-BCBB49DF-4C69-4EE9-8623-90287C09CC61 Q27004482-B54A044F-B8BD-467F-9974-EA6C52684E61 Q27664232-7ADBE5D9-ABB6-45D2-A894-ADCEB7264D80 Q28074247-9B2542C1-685D-4CE3-A803-CCC056FFAAD9 Q28384421-10632040-C1CC-4571-94EE-29FEA4947CF4 Q28480855-59F9DE03-7188-43E4-BF26-D629C71A5E5A Q28485999-F92C3F13-0689-4DD3-BE61-1D5FF3FD4D29 Q28538319-66DD1822-5392-421A-AA52-DCB8D04A05B4 Q28551033-86CEB1D0-635E-4541-8A06-E4F93C46FBBF Q28551297-2CA46BCE-679C-4F04-8989-C97891AA20CA Q28553119-91F6116F-6E37-417D-A88B-3D2828CB4904 Q28818217-BA9A7C50-D52D-4398-A791-ADFECE80AC94 Q30360811-36451731-C9CA-4EBE-B894-8328D1E85604 Q31102969-AE33AE94-BEB8-4826-8FE7-ECCC9692F5A9 Q31126318-5D5A9B18-5E14-4361-A396-E98EAC0841B8 Q33413454-C16A8566-5C89-48BD-B601-553AD8509DC3 Q33567352-AA238353-0018-40D8-B43E-D568704D0F94 Q33735589-F475479D-02E0-4588-B536-87CBFB717AE5 Q33823864-48CADFA9-0595-47CC-9DA2-BBE4C90FEBFB Q33873368-2297D9B4-43AF-411F-AF72-A2A4C49F9A4A Q34034062-214A4F1D-7410-465F-811D-875A7D77A129 Q34058316-6BC71A28-9650-4580-A22D-62A0C3057D34 Q34279727-91893F7B-B8AB-4AE6-91DC-A8F54633DB1F Q34290003-70B01774-9692-4679-83DE-F3F59DD7A4B0 Q34433240-AE9020A8-8A9D-42EF-983F-5C66D29D23D5 Q34737489-4C202D81-3306-434D-9A40-784BEA6CF729 Q34777926-86773A4E-26EF-414B-B274-749B064AD26F Q35042658-BABBAA1D-8A95-49B5-AD20-D1C213266FE8 Q35065890-EA78D34C-CE16-4F2B-B382-35656F1826D2 Q35066020-1F82AE02-5A7E-472B-A5A5-CB93340ACCA8 Q35139691-0813384D-7AFE-42B1-9075-E67D884E3D6A Q35155801-288C512F-9F3D-43D8-84E7-A61AC1BA4C19 Q35166484-7955DA1E-D856-4682-8C33-084F9B33C8A4 Q35598474-A2DDF294-D5C1-46E7-B5FA-E96E8702649B

P2860

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

http://www.wikidata.org/entity/Q33837706

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@ast

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@en

type

label

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@ast

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@en

prefLabel

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@ast

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@en

P1433

Q33837706-AE75A707-57A3-4C4B-A9E4-3FBBC1E71C60

P1476

Q33837706-E433D22F-16E2-4605-A405-A3BA187E0880

P2093

Q33837706-0CE78698-C165-46F9-B721-EFAE7DC66656

Q33837706-2A9FF435-5CAF-4D80-AD49-7BE9B828608B

Q33837706-36D4FCC3-2F16-43E1-BA0B-B36FCCF27870

Q33837706-38031F2B-E593-4F92-9A60-824BD9568058

Q33837706-45247699-EFFA-42E9-B62A-F236E3EB89FD

Q33837706-6CA58B17-C042-4DA3-8B18-888B39A44E8A

Q33837706-869B940F-0246-4B3A-9E8A-8DC39D18F2FD

Q33837706-9B938D60-4073-482F-98F4-5C7D95F18DF9

Q33837706-B1C94BA5-AD54-46E4-86CB-9D72B75C29EA

Q33837706-EA7BF295-2410-45B8-9898-2A21A8CDB2AC

P2860

Q33837706-05B24A01-E794-4AB9-A909-E4D3DA9E8286

Q33837706-0804F70C-5C9D-48BC-8FE6-4B83CA40D3BF

Q33837706-2C0FE805-92A2-41B8-AB0F-924AD3072C7C

Q33837706-2F80845F-0798-4B05-9249-C0E471FBB4C7

Q33837706-631A63F5-B610-4628-81E8-B6A5AA496D07

Q33837706-668C0595-0A0C-4C2C-9C37-685F5935487D

Q33837706-66C61682-1AF2-48E5-A399-87C806A3457A

Q33837706-6ED83714-976D-4158-9521-EADB20F03C8A

Q33837706-75031104-DBF1-433C-95AC-95BA104869E5

Q33837706-7F46C887-70BB-40A5-A524-E46D98560544

P304

Q33837706-81210F19-D8D4-4FAC-B9BF-2EA7623492CF

P31

Q33837706-09372749-1A3D-4935-955E-232F8F2B9899

P356

Q33837706-703C92B4-DED7-4637-AE15-57FE6CAE9640

P407

Q33837706-FB0AC608-66EC-4B7D-8A64-CEAFDD2C203F

P433

Q33837706-52A09617-D022-4B2F-96FA-3C2A056483FD

P478

Q33837706-A9FFA6C0-C388-40A0-9A37-D2940FAE4326

P50

Q33837706-03C5C12A-02AE-42FF-8B45-C4C5A94140F5

P577

Q33837706-3DC40C02-6C0B-4CBA-AD7A-CA5D8CDB31DF

P698

Q33837706-CF895D91-E552-4144-8FDB-7E04BAE43807

P921

Q33837706-54B9E9C0-E0E2-4981-B078-8B9C0447E9ED

Q33837706-AEC3D1F4-5B96-4854-9D96-C97F050D2A8D

P932

Q33837706-D5EE7AF8-F1A4-4254-BCE9-361126289005

P356

S0140-6736(09)60333-0

P1433

P1476

Moxifloxacin versus ethambutol ...... sed, controlled phase II trial

@en

P2093

Afranio L Kritski

http://www.w3.org/2001/XMLSchema#string

Anne Efron

http://www.w3.org/2001/XMLSchema#string

Carla Loredo

http://www.w3.org/2001/XMLSchema#string

Gilvan R Muzy De Souza

http://www.w3.org/2001/XMLSchema#string

Malathi Ram

http://www.w3.org/2001/XMLSchema#string

Marcus B Conde

http://www.w3.org/2001/XMLSchema#string

Michelle C Cezar

http://www.w3.org/2001/XMLSchema#string

Mohammad A Chaudhary

http://www.w3.org/2001/XMLSchema#string

Nadja P Graça

http://www.w3.org/2001/XMLSchema#string

William R Bishai

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

Outpatient gatifloxacin therapy and dysglycemia in older adults

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

Activity of moxifloxacin against mycobacteria

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

P304

1183-1189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(09)60333-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9670

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Richard E Chaisson

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19345831

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

phase II clinical trial

P932

2866651

http://www.w3.org/2001/XMLSchema#string